1
|
Papaleo N, Climent F, Tapia G, Luizaga L, Azcarate J, Bosch-Schips J, Muñoz-Marmol AM, Salido M, Lome-Maldonado C, Vazquez I, Colomo L. Round-robin testing for LMO2 and MYC as immunohistochemical markers to screen MYC rearrangements in aggressive large B-cell lymphoma. Virchows Arch 2024; 485:307-314. [PMID: 37368083 PMCID: PMC11329383 DOI: 10.1007/s00428-023-03584-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2023] [Revised: 05/25/2023] [Accepted: 06/16/2023] [Indexed: 06/28/2023]
Abstract
Aggressive large B-cell lymphomas (aLBCL) include a heterogeneous group of lymphomas with diverse biological features. One of the approaches to the diagnosis of aLBCL is based on the identification of MYC rearrangements (MYC-R), in addition to BCL2 and BCL6 rearrangements by genetic techniques, mainly fluorescent in situ hybridization (FISH). Because of the low incidence of MYC-R, the identification of useful immunohistochemistry markers to select cases for MYC FISH testing may be useful in daily practice. In a previous work, we identified a strong association between the profile CD10 positive/LMO2 negative expression and the presence of MYC-R in aLBCL and obtained good intralaboratory reproducibility. In this study, we wanted to evaluate external reproducibility. To evaluate whether LMO2 can be a reproducible marker between observers 50 aLBCL cases were circulated among 7 hematopathologists of 5 hospitals. Fleiss' kappa index for LMO2 and MYC were 0.87 and 0.70, respectively, indicating high agreement between observers. In addition, during 2021-2022, the enrolled centers included LMO2 in their diagnostic panels to evaluate prospectively the utility of the marker, and 213 cases were analyzed. Comparing LMO2 with MYC, the group of CD10 positive cases showed higher specificity (86% vs 79%), positive predictive value (66% vs 58%), likelihood positive value (5.47 vs 3.78), and accuracy (83% vs 79%), whereas the negative predictive values remained similar (90% vs 91%). These findings place LMO2 as a useful and reproducible marker to screen MYC-R in aLBCL.
Collapse
MESH Headings
- Humans
- LIM Domain Proteins/genetics
- LIM Domain Proteins/metabolism
- Biomarkers, Tumor/analysis
- Biomarkers, Tumor/genetics
- Proto-Oncogene Proteins c-myc/genetics
- Adaptor Proteins, Signal Transducing/genetics
- Adaptor Proteins, Signal Transducing/metabolism
- Adaptor Proteins, Signal Transducing/analysis
- Immunohistochemistry
- Gene Rearrangement
- Lymphoma, Large B-Cell, Diffuse/genetics
- Lymphoma, Large B-Cell, Diffuse/diagnosis
- Lymphoma, Large B-Cell, Diffuse/pathology
- Proto-Oncogene Proteins/genetics
- Reproducibility of Results
- Male
- Female
- Middle Aged
- Aged
- In Situ Hybridization, Fluorescence
- Predictive Value of Tests
- Adult
- Prospective Studies
- Aged, 80 and over
Collapse
Affiliation(s)
- Natalia Papaleo
- Department of Pathology, Parc Taulí Hospital Universitari, Institut d'Investigació i Innovació Parc Taulí (I3PT-CERCA), Barcelona, Spain
- Universitat Autonoma de Barcelona, Barcelona, Spain
- Universitat Pompeu Fabra, Barcelona, Spain
| | - Fina Climent
- Department of Pathology, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain
| | - Gustavo Tapia
- Universitat Autonoma de Barcelona, Barcelona, Spain
- Department of Pathology, Hospital Universitari Germans Trias I Pujol, Badalona, Barcelona, Spain
| | - Luis Luizaga
- Department of Pathology, Hospital Mutua Terrassa, Terrassa, Barcelona, Spain
| | - Juan Azcarate
- Department of Pathology, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain
| | - Jan Bosch-Schips
- Department of Pathology, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain
| | - Ana M Muñoz-Marmol
- Universitat Autonoma de Barcelona, Barcelona, Spain
- Department of Pathology, Hospital Universitari Germans Trias I Pujol, Badalona, Barcelona, Spain
| | - Marta Salido
- Department of Pathology, Hospital del Mar, Institute Hospital del Mar d'Investigacions Mediques (IMIM), Barcelona, Spain
| | - Carmen Lome-Maldonado
- Department of Pathology, Hospital del Mar, Institute Hospital del Mar d'Investigacions Mediques (IMIM), Barcelona, Spain
| | - Ivonne Vazquez
- Department of Pathology, Hospital del Mar, Institute Hospital del Mar d'Investigacions Mediques (IMIM), Barcelona, Spain
| | - Luis Colomo
- Universitat Pompeu Fabra, Barcelona, Spain.
- Department of Pathology, Hospital del Mar, Institute Hospital del Mar d'Investigacions Mediques (IMIM), Barcelona, Spain.
| |
Collapse
|
2
|
Papaleo N, Molina-Alvarez A, Onieva R, Fuertes D, Sanchez-Gonzalez B, Riera X, Lopez-Segura D, Lome-Maldonado C, Ara-Mancebo X, Yelamos J, Salido M, Vazquez I, Calvo X, Colomo L. Chromogenic LMO2 mRNA ISH Expression Correlates with LMO2 Protein and Gene Expression and Captures Their Survival Impact in Diffuse Large B-Cell Lymphoma, NOS. Cancers (Basel) 2024; 16:2378. [PMID: 39001439 PMCID: PMC11240605 DOI: 10.3390/cancers16132378] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2024] [Revised: 06/22/2024] [Accepted: 06/26/2024] [Indexed: 07/16/2024] Open
Abstract
BACKGROUND LMO2 is a relevant gene involved in B-cell ontogeny and a survival predictor of aggressive large B-cell lymphomas (aLBCL). Most studies assessing LMO2 mRNA expression have relied on microarray platforms or qRT-PCR methods, overlooking tissue morphology. In this study, we evaluate LMO2 RNA expression by chromogenic in situ hybridization (CISH) in normal tissue and in a series of 82 aLBCL. METHODS LMO2 CISH was performed in formalin-fixed paraffin-embedded tissues, scored by three different methods, and correlated with a transcriptome panel. RESULTS We obtained statistically significant results correlating the methods of evaluation with LMO2 protein expression and gene expression results. Normal tonsil tissue showed high levels of LMO2, particularly within the light zone of the germinal center. Conversely, in aLBCL, a notable reduction in LMO2 expression was noted, remarkably in cases carrying MYC rearrangements. Furthermore, significant results were obtained through overall survival and Cox regression survival analysis, incorporating International Prognostic Index data alongside LMO2 expression levels. CONCLUSIONS We show a reliable method to identify LMO2 mRNA expression by CISH, effectively capturing many of the reported biologic features of LMO2.
Collapse
Affiliation(s)
- Natalia Papaleo
- Department of Pathology, Hospital del Mar, Hospital del Mar Research Institute-IMIM, 08003 Barcelona, Spain
- Department of Pathology, Consorci Hospitalari Parc Tauli, Institut d'Investigació i Innovació Parc Taulí (I3PT), 08208 Sabadell, Spain
- Department of Morphological Sciences, Universitat Autonoma de Barcelona, 08193 Barcelona, Spain
- Department of Health and Experimental Sciences, Universitat Pompeu Fabra, 08003 Barcelona, Spain
| | - Andrea Molina-Alvarez
- Department of Pathology, Hospital del Mar, Hospital del Mar Research Institute-IMIM, 08003 Barcelona, Spain
| | - Ricard Onieva
- Department of Pathology, Consorci Hospitalari Parc Tauli, Institut d'Investigació i Innovació Parc Taulí (I3PT), 08208 Sabadell, Spain
| | - Diana Fuertes
- Research Unit Support, Institut d'Investigació i Innovació Parc Taulí (I3PT), 08208 Sabadell, Spain
| | - Blanca Sanchez-Gonzalez
- Department of Hematology, Hospital del Mar, Hospital del Mar Research Institute-IMIM, 08003 Barcelona, Spain
| | - Xenia Riera
- Department of Pathology, Hospital del Mar, Hospital del Mar Research Institute-IMIM, 08003 Barcelona, Spain
| | - David Lopez-Segura
- Department of Pathology, Hospital del Mar, Hospital del Mar Research Institute-IMIM, 08003 Barcelona, Spain
| | - Carmen Lome-Maldonado
- Department of Pathology, Hospital del Mar, Hospital del Mar Research Institute-IMIM, 08003 Barcelona, Spain
| | - Xavier Ara-Mancebo
- Department of Pathology, Hospital del Mar, Hospital del Mar Research Institute-IMIM, 08003 Barcelona, Spain
| | - Jose Yelamos
- Department of Pathology, Hospital del Mar, Hospital del Mar Research Institute-IMIM, 08003 Barcelona, Spain
| | - Marta Salido
- Department of Pathology, Hospital del Mar, Hospital del Mar Research Institute-IMIM, 08003 Barcelona, Spain
| | - Ivonne Vazquez
- Department of Pathology, Hospital del Mar, Hospital del Mar Research Institute-IMIM, 08003 Barcelona, Spain
| | - Xavier Calvo
- Department of Pathology, Hospital del Mar, Hospital del Mar Research Institute-IMIM, 08003 Barcelona, Spain
| | - Luis Colomo
- Department of Pathology, Hospital del Mar, Hospital del Mar Research Institute-IMIM, 08003 Barcelona, Spain
- Department of Health and Experimental Sciences, Universitat Pompeu Fabra, 08003 Barcelona, Spain
| |
Collapse
|
3
|
Targeting CD38 in Neoplasms and Non-Cancer Diseases. Cancers (Basel) 2022; 14:cancers14174169. [PMID: 36077708 PMCID: PMC9454480 DOI: 10.3390/cancers14174169] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2022] [Revised: 08/21/2022] [Accepted: 08/25/2022] [Indexed: 01/12/2023] Open
Abstract
Simple Summary CD38 remains an interesting target for anticancer therapy. Its relatively high abundance in neoplasms and crucial impact on NAD+/cADPR metabolism and the activity of T cells allows for changing the immune response in autoimmune diseases, neoplasms, and finally the induction of cell death. Antibody-dependent cell cytotoxicity is responsible for cell death induced by targeting the tumor with anti-CD38 antibodies, such as daratumumab. A wide range of laboratory experiments and clinical trials show an especially promising role of anti-CD38 therapy against multiple myeloma, NK cell lymphomas, and CD19- B-cell malignancies. More studies are required to include more diseases in the therapeutic protocols involving the modulation of CD38 activity. Abstract CD38 is a myeloid antigen present both on the cell membrane and in the intracellular compartment of the cell. Its occurrence is often enhanced in cancer cells, thus making it a potential target in anticancer therapy. Daratumumab and isatuximab already received FDA approval, and novel agents such as MOR202, TAK079 and TNB-738 undergo clinical trials. Also, novel therapeutics such as SAR442085 aim to outrank the older antibodies against CD38. Multiple myeloma and immunoglobulin light-chain amyloidosis may be effectively treated with anti-CD38 immunotherapy. Its role in other hematological malignancies is also important concerning both diagnostic process and potential treatment in the future. Aside from the hematological malignancies, CD38 remains a potential target in gastrointestinal, neurological and pulmonary system disorders. Due to the strong interaction of CD38 with TCR and CD16 on T cells, it may also serve as the biomarker in transplant rejection in renal transplant patients. Besides, CD38 finds its role outside oncology in systemic lupus erythematosus and collagen-induced arthritis. CD38 plays an important role in viral infections, including AIDS and COVID-19. Most of the undergoing clinical trials focus on the use of anti-CD38 antibodies in the therapy of multiple myeloma, CD19- B-cell malignancies, and NK cell lymphomas. This review focuses on targeting CD38 in cancer and non-cancerous diseases using antibodies, cell-based therapies and CD38 inhibitors. We also provide a summary of current clinical trials targeting CD38.
Collapse
|
4
|
Onaindia A, Santiago-Quispe N, Iglesias-Martinez E, Romero-Abrio C. Molecular Update and Evolving Classification of Large B-Cell Lymphoma. Cancers (Basel) 2021; 13:3352. [PMID: 34283060 PMCID: PMC8269067 DOI: 10.3390/cancers13133352] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2021] [Revised: 06/21/2021] [Accepted: 06/25/2021] [Indexed: 12/12/2022] Open
Abstract
Diffuse large B-cell lymphomas (DLBCLs) are aggressive B-cell neoplasms with considerable clinical, biologic, and pathologic diversity. The application of high throughput technologies to the study of lymphomas has yielded abundant molecular data leading to the identification of distinct molecular identities and novel pathogenetic pathways. In light of this new information, newly refined diagnostic criteria have been established in the fourth edition of the World Health Organization (WHO) consensus classification of lymphomas, which was revised in 2016. This article reviews the histopathological and molecular features of the various aggressive B-cell lymphoma subtypes included in the updated classification.
Collapse
Affiliation(s)
- Arantza Onaindia
- Bioaraba Health Research Institute, Oncohaematology Research Group, 01070 Vitoria-Gasteiz, Spain
- Osakidetza Basque Health Service, Araba University Hospital, Pathology Department, 01070 Vitoria-Gasteiz, Spain; (N.S.-Q.); (E.I.-M.); (C.R.-A.)
| | - Nancy Santiago-Quispe
- Osakidetza Basque Health Service, Araba University Hospital, Pathology Department, 01070 Vitoria-Gasteiz, Spain; (N.S.-Q.); (E.I.-M.); (C.R.-A.)
| | - Erika Iglesias-Martinez
- Osakidetza Basque Health Service, Araba University Hospital, Pathology Department, 01070 Vitoria-Gasteiz, Spain; (N.S.-Q.); (E.I.-M.); (C.R.-A.)
| | - Cristina Romero-Abrio
- Osakidetza Basque Health Service, Araba University Hospital, Pathology Department, 01070 Vitoria-Gasteiz, Spain; (N.S.-Q.); (E.I.-M.); (C.R.-A.)
| |
Collapse
|
5
|
Chapman J, Verdun RE, Lossos IS. Low LIM-domain only 2 (LMO2) expression in aggressive B cell lymphoma correlates with MYC and MYC/ BCL2 rearrangements, especially in germinal center cell-type tumors. Leuk Lymphoma 2021; 62:2547-2550. [PMID: 33988072 DOI: 10.1080/10428194.2021.1927020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Affiliation(s)
- Jennifer Chapman
- Department of Pathology and Laboratory Medicine, Division of Hematopathology, University of Miami/Sylvester Comprehensive Cancer Center, Miami, FL, USA
| | - Ramiro E Verdun
- Department of Medicine, Division of Hematology, University of Miami/Sylvester Comprehensive Cancer Center, Miami, FL, USA
| | - Izidore S Lossos
- Department of Medicine, Division of Hematology, University of Miami/Sylvester Comprehensive Cancer Center, Miami, FL, USA
| |
Collapse
|
6
|
Burkitt-Like Lymphoma with 11q Aberration: A Case Report and Review of a Rare Entity. Case Rep Hematol 2020; 2020:8896322. [PMID: 32963851 PMCID: PMC7495152 DOI: 10.1155/2020/8896322] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2020] [Revised: 08/27/2020] [Accepted: 08/28/2020] [Indexed: 12/21/2022] Open
Abstract
Burkitt-like lymphoma with 11q aberration is a rare diagnostic entity commonly occurring in children and young adults with a nodal presentation. This entity shares many similar morphologic and immunophenotypic features with conventional Burkitt lymphoma and other aggressive B-cell lymphomas, making its recognition challenging. However, the presence of its characteristic 11q gain/loss pattern is helpful in the diagnosis. We report a case of Burkitt-like lymphoma presenting as a right neck mass in a 17-year-old female patient that demonstrated no improvement with antibiotic therapy. The neoplasm displayed a diffuse proliferation of intermediate-sized atypical lymphoid cells with prominent nucleoli in a background of apoptotic debris, morphologically raising concern for conventional Burkitt lymphoma. Subsequent immunohistochemical and cytogenetic studies established the most likely diagnosis of Burkitt-like lymphoma with 11q aberration. Though rare, Burkitt-like lymphoma exhibits significant morphologic overlap with other high-grade B-cell lymphomas, making it an important entity to consider on the differential diagnosis of these lesions.
Collapse
|
7
|
Vazquez I, Papaleo N, Garcia E, Salido M, Salar A, Hernandez S, Calvo X, Colomo L. Clinical Interest of LMO2 Testing for the Diagnosis of Aggressive Large B-Cell Lymphomas. Cancers (Basel) 2020; 12:E884. [PMID: 32260556 PMCID: PMC7226002 DOI: 10.3390/cancers12040884] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2020] [Revised: 04/03/2020] [Accepted: 04/04/2020] [Indexed: 12/11/2022] Open
Abstract
MYC rearrangements usually confer aggressive biological behavior to large B-cell lymphomas. In this study, we aimed to evaluate the relevance of LMO2 detection to the clinical approach to these tumors. First, the ability of LMO2 loss of expression to recognize the presence of MYC rearrangements was evaluated. A series of 365 samples obtained from 351 patients, including 28 Burkitt lymphoma, 230 diffuse large B-cell lymphoma, 30 high-grade B-cell lymphoma with MYC and BCL2/BCL6 rearrangements, eight high-grade B-cell lymphoma-NOS, 43 transformed diffuse large B-cell lymphoma, and 26 high-grade follicular lymphomas was analyzed. Among the CD10-positive tumors prospectively analyzed in whole tissue sections, LMO2 negative expression obtained values of 88% sensitivity, 94% specificity, and 93% accuracy, proving the utility of LMO2 to screen MYC rearrangements. In addition, survival analyses were performed in a series of 155 patients. As per univariate analyses, the prognosis relevance of LMO2 was as useful as that of the diagnostic categories, MYC rearrangements, and MYC immunohistochemistry. Multivariate models revealed that both LMO2 (hazard ratio 0.51 p = 0.02) and IPI (hazard ratio 1.67 p < 0.005) were independent variables predicting overall survival. Finally, MYC and LMO2 mRNA expression were analyzed in a small group of cases. Taken together, these findings show the interest of LMO2 testing in large B-cell lymphomas.
Collapse
Affiliation(s)
- Ivonne Vazquez
- Department of Pathology, Hematopathology Section, Hospital del Mar, Institute of Investigacions Mediques-IMIM, Universitat Autonoma de Barcelona, 08003 Barcelona, Spain; (I.V.); (N.P.); (M.S.); (X.C.)
| | - Natalia Papaleo
- Department of Pathology, Hematopathology Section, Hospital del Mar, Institute of Investigacions Mediques-IMIM, Universitat Autonoma de Barcelona, 08003 Barcelona, Spain; (I.V.); (N.P.); (M.S.); (X.C.)
| | - Eugenia Garcia
- Department of Pathology-IdiPAZ, Hospital Universitario La Paz, 28046 Madrid, Spain;
| | - Marta Salido
- Department of Pathology, Hematopathology Section, Hospital del Mar, Institute of Investigacions Mediques-IMIM, Universitat Autonoma de Barcelona, 08003 Barcelona, Spain; (I.V.); (N.P.); (M.S.); (X.C.)
| | - Antonio Salar
- Department of Hematology, Hospital del Mar, Institute of Investigacions Mediques-IMIM, Universitat Autonoma de Barcelona, 08003 Barcelona, Spain;
| | - Silvia Hernandez
- Department of Health and Experimental Sciences, Universitat Pompeu Fabra, 08003 Barcelona, Spain;
| | - Xavier Calvo
- Department of Pathology, Hematopathology Section, Hospital del Mar, Institute of Investigacions Mediques-IMIM, Universitat Autonoma de Barcelona, 08003 Barcelona, Spain; (I.V.); (N.P.); (M.S.); (X.C.)
| | - Luis Colomo
- Department of Pathology, Hematopathology Section, Hospital del Mar, Institute of Investigacions Mediques-IMIM, Universitat Autonoma de Barcelona, 08003 Barcelona, Spain; (I.V.); (N.P.); (M.S.); (X.C.)
- Department of Health and Experimental Sciences, Universitat Pompeu Fabra, 08003 Barcelona, Spain;
| |
Collapse
|